MOGAMULIZUMAB
EORTC-1820-CLTF
Phase 2 small_molecule active
Quick answer
MOGAMULIZUMAB for Cutaneous T-cell lymphoma, a category of cancers of lymphocytes (a type of white blood cells) that primarily involve the skin, Cutaneous T-cell lymphoma (Mycosis Fungoides (MF)) and Sézary Syndrome (SS)) is a Phase 2 program (small_molecule) at Cancer Prevention Pharma (Ireland) Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Cancer Prevention Pharma (Ireland) Limited
- Indication
- Cutaneous T-cell lymphoma, a category of cancers of lymphocytes (a type of white blood cells) that primarily involve the skin, Cutaneous T-cell lymphoma (Mycosis Fungoides (MF)) and Sézary Syndrome (SS))
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active